Systemic effects of interferons after oral administration in animals and humans

American Journal of Veterinary Research

Volumn 66, Issue 1, 2005, Pages 164-176

  Cummins, Joseph M ^a   Krakowka, G Steven ^b   Thompson, Chad G ^c  

^a Amarillo Biosciences Inc   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON A-D; ANTIINFECTIVE AGENT; ARTIFICIAL TEAR; BETA INTERFERON; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; HUMAN INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; INTERFERON ANTIBODY; IODINE 123; IODINE 125; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYELIN BASIC PROTEIN; OVALBUMIN; PLACEBO; PROTEINASE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON; STREPTOZOCIN; TAU INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC NEUROPATHY; ALLERGY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHMA; AUTOIMMUNE DISEASE; BIRD DISEASE; CAT DISEASE; CATTLE DISEASE; CHRONIC GRANULOMATOUS DISEASE; CONDYLOMA; DOG; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; HEPATITIS B; HEPATITIS C; HORSE; HUMAN; HYPERSENSITIVITY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; KERATOCONJUNCTIVITIS SICCA; LISTERIOSIS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; OPTIMAL DRUG DOSE; PYODERMA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION; SEMLIKI FOREST ALPHAVIRUS; SIDE EFFECT; SINGLE DRUG DOSE; SPECIES DIFFERENCE; SWINE DISEASE; T LYMPHOCYTE SUBPOPULATION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ADMINISTRATION, ORAL; ANIMALS; HUMANS; INTERFERONS;

ALPHAVIRUS; ANIMALIA; AVES; BOS TAURUS; CANIS FAMILIARIS; EQUUS CABALLUS; FELIS CATUS; HEPATITIS C VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RNA VIRUSES; SEMLIKI FOREST VIRUS; SUS SCROFA; VACCINIA; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 13444273273     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.164     Document Type: Review

References (171)

1. Huston DP. The biology of the immune system. JAMA 1997;278:1804-1814.
2. Uthaisangsook S, Day NK, Bahna SL, et al. Innate immunity and its role against infections. Ann Allergy Asthma Immunol 2002;88:253-265.
3. Oppenheim JJ, Feldman M. introduction to the role of cytokines in innate host defense and adaptive immunity In: Oppenheim JJ, Feldman M, Durum SK, et al, eds. Cytokine references. New York: Academic Press Inc, 2001;3-20.
4. Oppenheim JJ. Cytokines: past, present, and future. Int J Hematol 2001;74:3-8.
5. Gangur V, Oppenheim JJ. Are chemokines essential or secondary participants in allergic responses? Ann Allergy Asthma Immunol 2000;84:569-581.
6. Oppenheim JJ, Saldatvala J. Cytokines and their receptors. In: Oppenheim JJ, Rossio JL, Gearing AJH, eds. Clinical applications of cytokines. Role in pathogenesis, diagnosis and therapy. New York: Oxford University Press, 1993;3-15.
7. Stroud RM, Laporte S, Wells JA. Cytokine-receptor signaling at the molecular level. In: Oppenheim JJ, Feldman M, Durum SK, et al, eds. Cytokine references. New York: Academic Press Inc, 2001; 21-34.
8. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of septic syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;30:S58-S63.
9. Czuprynski CJ, Haak-Frendscho M. Cytokines in bacterial and fungal infections. In: Remick DG, Friedland JS, eds. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker Inc, 1997; 591-608.
10. Barnes PJ. Cytokine modulators as novel therapy in asthma. Annu Rev Pharmacol Toxicol 2002;42:81-98.
11. Feldman M, Brennan FM. Cytokines and disease. In: Oppenheim JJ, Feldman M, Durum SK, et al, eds. Cytokine references. New York: Academic Press Inc, 2001;35-51.
12. Janik JE, Gause BL, Oppenheim JJ. Principles of cytokine biotherapy. In: Oppenheim JJ, Rossio JL, Gearing AJH, eds. Clinical applications of cytokines. Role in pathogenesis, diagnosis and therapy New York: Oxford University Press, 1993;129-134.
13. Sheridan WP, Hunt P, Simonet S, et al. Hernatological effects of cytokines. In: Remick DG, Friedland JS, eds. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker Inc, 1997;487-505.
14. Strander H. Taxicities of interferons. In: Stuart-Harris R, Penny R, eds. Clinical applications of the interferons. London: Chapman & Hall Medical, 1997;331-363.
15. Bocci V. Pharmacology and side-effects of interferons. Antiviral Res 1994;24:111-119.
16. Stylianou E, Aukrust P, Muller E et al. Complex effects of interferon-α on the cytokine network in HIV infection - possible contribution to immunosuppression. Cytokine 2001;14:56-62.
17. Kulmatycki KM, Jamali F. Therapeutic relevance of altered cytokine expression. Cytokine 2001;14:1-10.
18. Actimmune interferon gamma-1b. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;1731-1733.
19. Alferon N Injection interferon alfa-n3. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;1704-1706.
20. Avonex interferon beta-1a. In: Physician's desk reference 58th ed. Montvale, NJ: Medical Economics Co, 2004;972-977.
21. Betaseron interferon beta-1b. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;899-903.
22. Infergen interferon alfacon-1. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;1736-1739.
23. Intron A interferon alfa-2b recombinant and Peg-Intron peginterferon alfa-2b. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;054-3062.
24. Pegasys peginterferon alfa-2a. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;2931-2935.
25. Rebif interferon beta-1a. In: Physician's desk reference 58th ed. Montvale, NJ: Medical Economics Co, 2004;3136-3139.
26. Roferon-A interferon alfa-2a recombinant. In: Physician's desk reference. 58th ed. Montvale, NJ: Medical Economics Co, 2004;2941-2945.
27. Bocci V. The oropharyngeal delivery of interferon: where are we and where do we need to go? J Interferon Cytokine Res 1999;19:859-861.
28. Bocci V, Von Bremen K, Corradeschi R, et al. What is the role of cytokines in human colostrum? J Biol Regul Homeost Agents 1991;5:121-124.
29. Garofalo RP, Goldman AS. Cytokines, chemokines and colony stimulating factors in human milk: the 1997 update. Biol Neonate 1998;74:134-142.
30. Mushtaha AA, Schmalstieg FC, Hughes Jr TK, et al. Chemokinetic agents for monocytes in human milk: possible role of tumor necrosis factor-α. Pediatr Res 1989;25:629-633.
31. Rudloff HE, Schmalstieg, Jr. FC, Mushtaha AA, et al. Tumor necrosis factor-α in human milk. Pediatr Res 1992;31:29-33.
32. Goldman AS, Chheda S, Garofalo R, et al. Cytokines in human milk: properties and potential effects upon the mammary gland and the neonate. J Mammary Gland Biol Neoplasia 1996;1:251-258.
33. Goldman AS. Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective. J Nutr 2000;130:426S-431S.
34. Goldman AS. The immunological system in human milk: the past - a pathway to the future. Adv Nutr Res 2001;10:15-37.
35. Hamosh M. Bioactive factors in human milk. Pediatr Clin North Am 2001;48:69-86.
36. Rohan LC, Edwards RP, Kelly LA, et al. Optimization of the weck-Cel collection method for quantitation of cytokines in mucosal secretions. Clin Diagn Lab Immunol 2000;7:45-48.
37. Leigh JE, Steele C, Wormley FL, et al. Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:373-380.
38. Al-Harthi L, Wright DJ, Anderson D, et al. The impact of the ovulatory cycle on cytokine production: evaluation of systemic cervicovaginal, and salivary compartments. J Interferon Cytokine Res 2000;20:719-724.
39. Fujioka N, Akazawa R, Sakamoto K, et al. Potential application of human interferon-α in microbial infections of the oral cavity. J Interferon Cytokine Res 1995;15:1047-1051.
40. Wozniak KL, Arribas A, Leigh JE, et al. Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol 2002;17:100-107.
41. Larsson B, Palmberg L, Palmberg PO, et al. Effect of exposure to swine dust on levels of IL-8 in airway lavage fluid. Thorax 1997;52:638-642.
42. Turner RB, Weingand KW, Yeh C, et al. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin Infect Dis 1998;26:840-846.
43. Sheeran P, Jafti H, Carubelli C, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999;18:115-122.
44. Sim TC, Grant JA, Hilsmeier KA, et al. Proinflammatory cytokines in nasal secretions of allergic subjects after antigen challenge. Am J Respir Crit Care Med 1994;149:339-344.
45. Teran LM, Seminario MC, Shute JK, et al. RANTES, macrophage-inhibitory protein 1α, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children. J Infect Dis 1999;179:677-681.
46. Heikkinen T, Shenoy M, Goldblum RM, et al. Quantification of cytokines and inflammatory mediators in samples of nasopharyngeal secretions with unknown dilution. Pediatr Res 1999;45:230-234.
47. Weido AJ, Reece LM, Alam R, et al. Intranasal fluticasone propionate inhibits recovery of chemokines and other cytokines in nasal secretions in allergen-induced rhinitis. Ann Allergy Asthma Immunol 1996;77:407-415.
48. Ohkubo K, Ikeda M, Pawankar R, et al. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge. Rhinology 1998;36:156-161.
49. Cummins JM, Beilharz MW, Krakowka S. Oral use of interferon. J Interferon Cytokine Res 1999;19:853-857.
50. Bocci V. Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Clin Pharmacokinet 1991;21:411-416.
51. Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.
52. Tovey MG, Bandu MT, Begon-Lewis J, et al. Antiviral activity of bovine interferons on primate cells. J Gen Virol 1977;36:341-344.
53. Carter WA. Mechanisms of cross-species activity of mammalian interferons. Pharmacol Ther 1979;7:245-252.
54. Carter WA, Davis LR Jr, Chadha KC. Porcine leukocyte interferon and antiviral activity in human cells. Mol Pharmacol 1979;15:685-690.
55. Gressor I, Bandu MT, Brouty-Boye D, et al. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 1974;251:543-545.
56. Branca AA. High-affinity receptors for human interferon in bovine lung and human placenta. J Interferon Res 1986;6:305-311.
57. Meister A, Uze G, Mogensen KE, et al. Biological activities and receptor binding of two human recombinant interferon and their hybrids. J Gen Virol 1986;67:1633-1643.
58. Chambers PJ, Saltis J, Alin P et al. Receptors for human interferon-α on bovine cells: specificity and tissue distribution. Immunopharmacol Immunotoxicol 1990;12:513-525.
59. Pestka S. The human interferon-a species and hybrid proteins. Seminars Oncol 1997;24(suppl 9):S9-4-S9-17.
60. Desmyter J, Stewart II WE. Molecular modification of interferon: attainment of human interferon in a conformation active on cat cells but inactive on human cells. Virology 1976;70:451-458.
61. Martin V, Najbar W, Gueguen S, et al. Treatment of canine parvovirual enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 2002;89:115-127.
62. Miyazaki T, Nozawa N, Kobayashi T. Clinical trial results on the use of a recombinant feline interferon-omega to protect Japanese pearl oysters Pinctada fucata martensii from akoya-virus infection. Dis Aquat Organ 2000;43:15-26.
63. Cantell K, Pyhala L. Circulating interferon in rabbits after administration of human interferon by different route. J Gen Virol 1973;20:97-104.
64. Gibson DM, Cotler S, Spiegel HE, et al. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985;5:403-408.
65. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following IV infusion and bolus, IM, and PO administrations to African Green monkeys. J Interferon Res 1984;4:399-409.
66. Eid P, Meritet JF, Maury C, et al. Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. J Interferon Cytokine Res 1999;19:157-169.
67. Beilharz MW, McDonald W, Watson MW et al. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J Interferon Cytokine Res 1997; 17:625-630.
68. Williams BRG. Interferons. In: Lederberg J, ed. Encyclopedia of microbiology. Vol 2. 2nd ed. New York: Academic Press Inc, 2000;826-841.
69. Meritet JF, Maury C, Tovey MG. Effects of oromucosal administration of IFN-α on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen. J Interferon Cytokine Res 2001;21:583-593.
70. Takayama S, Iwaki K, Nishida Y, et al. Effects of oral administration of interferon-α on antibody production in mice with induced tolerance. J Interferon Cytokine Res 1999;19:895-900.
71. Satoh YI, Kasama K, Kuwabara M, et al. Suppression of late asthmatic response by low-dose oral administration of interferon-? in the guinea pig model of asthma. J Interferon Cytokine Res 1999;19:887-894.
72. Nakajima A, Sokawa Y. Induction of blood 2′,5′-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-α. J Interferon Cytokine Res 2002;22:397-402.
73. Dron M, Meritet J-E Dandoy-Dron E et al. Molecular cloning of ADIR, a novel interferon responsive gene encoding a protein related to the torsins. Genomics 2002;79:315-325.
74. Meritet JF, Maury C, Tovey MG. Induction of tolerance to recombinant therapeutic proteins. J Interferon Cytokine Res 2001;21:1031-1038.
75. Fleischmann WR Jr, Fields EE, Wang JL, et al. Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc Soc Exp Biol Med 1991?197:424-430.
76. Fleischmann WR Jr, Koren S, Fleischmann CM. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 1992;201:200-207.
77. Koren S, Fleischmann WR Jr. Orally administered interferons suppress bone marrow function. Proc Soc Exp Biol Med 1993;204:155-164.
78. Schafer TW, Liebermann M, Cohen M, et al. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972?176:1326-1327.
79. Tovey MG, Maury C. Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999;19:145-155.
80. Schellekens H, Geelen G, Meritet J-F, et al. Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res 2001;21:575-581.
81. Bosio E, Beilharz MW, Watson MW, et al. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J Interferon Cytokine Res 1999;19:869-876.
82. Lawson CM, Beilharz MW. Short communication: low-dose oral use of interferon inhibits vitally induced myocarditis. J Interferon Cytokine Res 1999;19:863-867.
83. Bosio E, Cluning CL, Beilharz M. Low-dose orally administered Type I interferon reduces splenic B cell numbers in mice. J Interferon Cytokine Res 2001;21:721-728.
84. Nagao Y, Yamashiro K, Hara N, et al. Oral-mucosal administration of IFN-α potentiates immune response in mice. J Interferon Cytokine Res 1998;18:661-666.
85. Degre M, Bukholm G. Orally administered interferon-? but not tumor necrosis factor-α suppress infection with Salmonella typhimurium in a mouse model. J Biol Regul Homeost Agents 1995;9:15-20.
86. Kaido TJ. Intranasal administration of IFN? and ? inhibits the development of visceral tumor metastases. J Interferon Cytokine Res 1997;17:31-36.
87. Fleischmann WR Jr, Masoor J, Wu TY, et al. Orally administered IFN-α acts alone and in synergistic combination with intraperitoneally administered IFN-α to exert an antitumor effect against B16 melanoma in mice. J Interferon Cytokine Res 1998;18:17-20.
88. Segerer S, Hudkins K, Taneda S, et al. Oral interferon-? treatment of mice with cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2002;39:876-888.
89. Brod SA, Khan M. Oral administration of IFN-αa is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 1996;9:11-20.
90. Vriesendorp FJ, Flynn RE, Khan M, et al. Oral administration of type I interferon modulates the course of experimental allergic neuritis. Autoimmunity 1996;24:157-165.
91. Brod SA, Nelson L, Rui J, et al. Ingested interferon alpha induces Mx RNA. Cytokine 1999;11:492-499.
92. Brod SA, Burns DK. Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 1994;44:1144-1148.
93. Nelson PA, Akselband Y, Dearborn SM, et al. Effect of oral beta interferon on subsequent immune responsiveness. Ann NY Acad Sci 1996;778:145-155.
94. Brod SA, Scott M, Burns D, et al. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 1995;15:115-122.
95. Soos JM, Mujtaba MG, Subramaniam PS, et al. Oral feeding of interferon-α can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J Neuroimmunol 1997;75:43-50.
96. Soos JM, Shiffenbauer J, Johnson HM. Method for treatment of autoimmune diseases using interferon tau. Described and claimed in Patent No. WO97/33607, Sept 18, 1997.
97. Sobel DO, Ahvazi B. Alpha-interferon inhibits the development of diabetes in NOD mice. Diabetes 1998;47:1867-1872.
98. Brod SA, Malone M, Darcan S, et al. Ingested interferon α suppresses type I diabetes in non-obese diabetic mice. Diabetologia 1998;41:1227-1232.
99. Tanaka-Kataoka M, Kunikata T, Takayama S, et al. Short communication: oral use of interferon-α delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. J Interferon Cytokine Res 1999;19:877-879.
100. Brod SA, Katz S, Phan T, et al. Ingested interferon-α prevents allograft islet transplant rejection. Transplantation 2000;69:2162-2166.
101. Yoshino S. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp Mol Pathol 1995;62:123-130.
102. Yoshino S. Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp Immunol Microbiol Infect Dis 1996;19:133-138.
103. Yoshino S. Suppression of adjuvant arthritis in rats by oral administration of type II collagen in combination with type I interferon. J Pharm Pharmacol 1996;48:702-705.
104. Tompkins MD, Cummins JM. Response of feline leukemia virus-induced nonregenerative anemia to oral administration of an interferon-containing preparation. Feline Pract 1982;12(3):6-15.
105. Steed VP. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract 1987;17(3):24-30.
106. Cummins JM, Tompkins MB, Olsen RG, et al. Oral use of human alpha interferon in cats. J Biol Response Mod 1988;7:513-523.
107. Kociba GJ, Garg RC, Kahn KNM, et al. Effects of orally administered interferon-α on the pathogenesis of feline leukemia virus-induced erythroid aplasia. Comp Haematol Int 1995;5:79-83.
108. McCaw DL, Boon GD, Jergens AE, et al. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 2001;37:356-363.
109. Gilger BC, Rose PD, Davidson MG, et al. Low-dose oral administration of interferon-α for the treatment of immune-mediated keratoconjunctivitis sicca in dogs. J Interferon Cytokine Res 1999;19:901-905.
110. Thompson LA, Grieshaber TL, Glickman L, et al. Human recombinant interferon alpha-2b for management of idiopathic recurrent superficial pyoderma in dogs: a pilot study. Vet Ther 2004; 5:75-81.
111. Stokking LB, Ehrhart EJ, Lichtensteiger CA, et al. Pigmented epidermal plaques in three dogs. J Am Anim Hosp Assoc 2004;40:411-417.
112. Moore BR, Krakowka S, Cummins JM, et al. Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet Immunol Immunopathol 1996;49:347-358.
113. Moore I, Horney B, Day K, et al. Treatment of inflammatory airway disease in young standardbreds with interferon alpha. Can Vet J 2004;45:594-601.
114. Seahorn TL, Carter GK, Martens JG, et al. Effects of human alpha interferon on experimentally induced equine herpes virus-1 infection in horses. Am J Vet Res 1990;51:2006-2010.
115. Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol Biother 1990;2:211-216.
116. Cummins JM, Mock RE, Shive BW, et al. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet Immunol Immunopathol 1995;45:355-360.
117. Georgiades J. Effect of low dose natural human interferon alpha given into the oral cavity on the recovery time and death loss in feedlot hospital pen cattle: a field study. Arch Immunol Ther Exp (Warsz) 1993;41:205-207.
118. Cummins JM, Hutcheson DP. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp (Warsz) 1993;41:193-197.
119. Cummins JM, Guthrie D, Hutcheson DP, et al. Natural human interferon-α administered orally as a treatment of bovine respiratory disease complex. J Interferon Cytokine Res 1999; 19:907-910.
120. Young AS, Maritim AC, Kariuki DR et al. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology 1990;101:201-209.
121. Cummins JM, Gawthrop J, Hutcheson DP, et al. The effect of low dose oral human interferon alpha therapy on diarrhea in veal calves. Arch Immunol Ther Exp (Warsz) 1993;41:199-203.
122. Fulton RW, Teeter RG, Cummins JM, et al. The use of interferon modulates the negative effects of heat stress on poultry production. Arch Immunol Ther Exp (Warsz) 1993;41:209-212.
123. Marcus PI, Van Der Heide L, Sekellick MJ. Short communication: interferon action on avian viruses. I. Oral administration of chicken interferon-α ameliorates Newcastle disease. J Interferon Cytokine Res 1999;19:881-885.
124. Pei J, Sekellick MJ, Marcus PI, et al. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J Interferon Cytokine Res 2001;21:1071-1077.
125. Jarosinski KW, Jia W, Sekellick MJ, et al. Cellular responses in chickens treated with IFN-α orally or inoculated with recombinant Marek's disease virus expressing IFN-α. J Interferon Cytokine Res 2001;21:287-296.
126. Orinda GO, Wright IG, Leatch G, et al. Human interferon alpha fails to inhibit the development of Babesia bigemina and Anaplasma marginale infections in cattle. Vet Parasitol 1993;47:149-155.
127. Diez RA, Perdereau B, Falcoff E. From old results to new perspectives: a look at interferon's fate in the body. J Interferon Res 1987;7:553-557.
128. Smith JK, Siddiqui AA, Modica LA, et al. Interferon-α upregulates gene expression of Aquaporin-5 in human parotid glands. J Interferon Cytokine Res 1999;19:929-935.
129. Smith JK, Siddiqui AA, Modica LA, et al. Oral use of interferon-α stimulates ISG-15 transcription and production by human buccal epithelial cells. J Interferon Cytokine Res 1999; 19:923-928.
130. Smith JK, Chi DS, Krishnaswamy G, et al. Effect of interferon α on HLA-DR expression by human buccal epithelial cells. Arch Immunol Ther Exp (Warsz) 1996;44:83-88.
131. Nguyen KB, Cousens LP, Doughty LA, et al. Interferon α/β-mediated inhibition and promotion of interferon α: STAT 1 resolves a paradox. Nat Immunol 2000;1:70-76.
132. Mughini L. Effects of interferon alpha administered by peroral route on lymphomonocytes' subpopulations of peripheral blood in healthy volunteers. Clin Ter 2000;151(suppl 1):3-12.
133. Kaiser G, Jaeger H, Birkmann J, et al. Low-dose oral natural human interferon-α in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS 1992; 6:563-569.
134. Hulton MR, Levin D, Freedman L. Randomized, placebo-controlled, double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr 1992;5:1084-1090.
135. Katabira ET, Sewankambo NK, Mugerwa RD, et al. Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. Sex Transm Infect 1998;74:265-270.
136. 3. J Acquir Immune Defic Syndr 1999; 22:348-357.
137. Sperber SJ, Gocke DJ, Haberzettl CA, et al. Low-dose oral recombinant interferon-α in patients with HIV-1 infection: a blinded pilot study. AIDS 1993;7:693-697.
138. Yasuda K, Ohashi Y, Matsushima T, et al. Low-dose oral interferon-α in the treatment of chronic viral hepatitis type-B: a double-blinded, randomized, placebo-controlled, clinical trial. Curr Ther Res Clin Exp 2000;61:245-254.
139. Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003;9:342-348.
140. Witt PL, Goldstein D, Storer BE, et al. Absence of biological effects of orally administered interferon-βSER. J Interferon Res 1992;12:411-413.
141. Dhingra K, Duvic M, Hymes S, et al. A phase-I clinical study of low-dose oral interferon-α. J Immunother 1993;14:51-55.
142. Arnaoudova V. Treatment and prevention of acute respiratory virus infections in children with leukocytic interferon. Rev Roum Med Virol 1976;27:83-88.
143. Lecciones JA, Abejar NH, Dimaano EE, et al. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res 1998;18:647-652.
144. Montevecchi L, Caprio G, Vecchione A. Preliminary note on the use of interferon alpha by peroral route in HPV lesions. Clin Ter 2000;151(suppl 1):29-34.
145. Palomba M, Melis GB. Oral use of interferon therapy in cervical human papillomavirus infection. Clin Ter 2000;151 (suppl 1):59-61.
146. Biamonti A, Cangialosi M, Brozzo R, et al. Peroral alpha-interferon therapy in HPV-lesions of the lower female genital tract: preliminary results. Clin Ter 2000;151(suppl 1):53-58.
147. Bastinaelli C, Caruso MT, Marcellini GF. New treatment of viral genital lesions with low dosage of interferon alpha by oropharyngeal absorption. Clin Ter 2000;151(suppl 1):23-28.
148. Koech DK, Obel AO, Minowada J, et al. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol Biother 1990;2:91-95.
149. Koech DK, Obel AO. Efficacy of KEMRON (low dose oral natural interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). E African Med J 1990;67:SS64-SS70.
150. Obel AO, Koech KD. Outcome of intervention with or without low dose oral interferon alpha in thirty-two HIV-1 seropositive patients in a referral hospital. E African Med J 1990;67:SS71-SS76.
151. Babiuch L, Mian M, Kaminska E, et al. An interim report on the effect of natural human interferon alpha (IFN-α) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1). Arch Immunol Ther Exper (Warsz) 1993;41:213-219.
152. Jordan WC. Three open-label studies of oral interferon alpha in the treatment of HIV disease. J Natl Med Assoc 1994;86:257-262.
153. Wright S, Hutcheson D, Cummins JM. Low dose oral interferon alpha 2a in seropositive patients: a double-blind, placebo-controlled trial. Biotherapy 1998;11:229-234.
154. Benkendorfer TR, Ericsson AD, Klgadye FC, et al. Acquired immunodeficiency syndrome treated with VIRON. Explore 1992;3:9-13.
155. Zielinska W, Paszkiewicz J, Korczak A, et al. Treatment of fourteen chronic active HBsAg+, HBeAg+ hepatitis patients with low dose natural human interferon alpha administered orally. Arch Immunol Ther Exp (Warsz) 1993;41:241-251.
156. Balcerska A, Bohdan Z, Drozynska E, et al. Evaluation of the efficacy of natural human interferon alpha lozenges on the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies. Arch Immunol Ther Exp (Warsz) 1993; 41:221-227.
157. Caban J, Mossor-Ostrowska J, Zyrkowska-Bieda T, et al. Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch Immunol Ther Exp (Warsz) 1993;41:229-235.
158. Georgiades JA. Natural human interferon-? may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus. Arch Immunol Ther Exp (Warsz) 1996;44:11-22.
159. Tsanev R, Ivanov I. Infectious diseases. In: Hollinger MA, ed. Immune interferon. Properties and clinical applications. Boca Raton, Fla: CRC Press Inc, 2002;53-58.
160. Cummins JM, Pruitt B. Low-dose oral use of human interferon-α in cancer patients. J Interferon Cytokine Res 1999; 19:937-941.
161. Cummins JM, Georgiades JA. How it began. Arch Immunol Ther Exp (Warsz) 1993;41:169-172.
162. Cummins MJ, Papas A, Kammer G, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon alpha administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-593.
163. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren's syndrome. J Interferon Cytokine Res 1998;18:255-262.
164. Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-αadministered by the oral mucosal route: a phase II clinical trial. J Interferon Cytokine Res 1999;19:943-951.
165. Brod SA, Kerman RH, Nelson L, et al. Ingested IFN-α has biological effects in humans with relapsing-remitting multiple sclerosis. Mult Scler 1997;3:1-7.
166. Brod SA, Lindsey JW, Vriesendorp FS, et al. Ingested IFN-α: Results of a pilot study in relapsing-remitting MS. Neurology 2001;57:845-852.
167. Brod SA, Atkinson M, Lavis VR, et al. Ingested IFN-α preserves residual β cell function in type I diabetes. J Interferon Cytokine Res 2001;21:1021-1030.
168. Russell IJ, Michalek JE, Kang YK, et al. Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-α . J Int Cytokine Res 1999; 19:961-968.
169. Hutchinson VA, Angenend JL, Mok WL, et al. Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha. Mol Biother 1990;2:160-164.
170. Hutchinson VA, Mok WL, Angenend JL, et al. Chronic major aphthous stomatitis: oral treatment with low-dose α -interferon. Mol Biother 1990;2:217-220.
171. Pedersen A. IFN-α cream in the treatment of oral lichen planus. Oral Dis 1998;4:155-156.